Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1989 Apr;27(4):435–444. doi: 10.1111/j.1365-2125.1989.tb05391.x

Genetically-determined interaction between propafenone and low dose quinidine: role of active metabolites in modulating net drug effect.

C Funck-Brentano 1, H K Kroemer 1, H Pavlou 1, R L Woosley 1, D M Roden 1
PMCID: PMC1379722  PMID: 2719900

Abstract

1. Quinidine is a potent inhibitor of the genetically-determined debrisoquine 4-hydroxylation. Oxidation reactions of several other drugs, including the 5-hydroxylation of the new antiarrhythmic drug propafenone, depend on the isozyme responsible for debrisoquine 4-hydroxylation. 2. The effect of quinidine on the debrisoquine phenotype-dependent 5-hydroxylation and the pharmacological activity of propafenone was studied in seven 'extensive' metabolizers and two 'poor' metabolizers of the drug receiving propafenone for the treatment of ventricular arrhythmias. 3. In patients with the extensive metabolizer phenotype, quinidine increased mean steady-state plasma propafenone concentrations more than two fold, from 408 +/- 351 (mean +/- s.d.) to 1096 +/- 644 ng ml-1 (P less than 0.001), decreased 5-hydroxypropafenone concentrations from 242 +/- 196 to 125 +/- 97 ng ml-1 (P less than 0.02) and reduced propafenone oral clearance by 58 +/- 23%. 4. Despite these changes in plasma concentrations, electrocardiographic intervals and arrhythmia frequency were unaltered by quinidine coadministration, indicating that 5-hydroxypropafenone contributes to the pharmacologic effects of propafenone therapy in extensive metabolizers. 5. In contrasts, plasma concentrations of propafenone and 5-hydroxypropafenone remained unchanged in the two patients with the poor metabolizer phenotype. 6. Biotransformation of substrates for the debrisoquine pathway can be markedly perturbed by even low doses of quinidine; interindividual variability in drug interactions may have a genetic component.

Full text

PDF
435

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Axelson J. E., Chan G. L., Kirsten E. B., Mason W. D., Lanman R. C., Kerr C. R. Food increases the bioavailability of propafenone. Br J Clin Pharmacol. 1987 Jun;23(6):735–741. doi: 10.1111/j.1365-2125.1987.tb03109.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Brinn R., Brøsen K., Gram L. F., Haghfelt T., Otton S. V. Sparteine oxidation is practically abolished in quinidine-treated patients. Br J Clin Pharmacol. 1986 Aug;22(2):194–197. doi: 10.1111/j.1365-2125.1986.tb05250.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Brøsen K., Gram L. F., Haghfelt T., Bertilsson L. Extensive metabolizers of debrisoquine become poor metabolizers during quinidine treatment. Pharmacol Toxicol. 1987 Apr;60(4):312–314. doi: 10.1111/j.1600-0773.1987.tb01758.x. [DOI] [PubMed] [Google Scholar]
  4. Dayer P., Balant L., Kupfer A., Striberni R., Leemann T. Effect of oxidative polymorphism (debrisoquine/sparteine type) on hepatic first-pass metabolism of bufuralol. Eur J Clin Pharmacol. 1985;28(3):317–320. doi: 10.1007/BF00543330. [DOI] [PubMed] [Google Scholar]
  5. EVANS D. A., MANLEY K. A., McKUSICK V. A. Genetic control of isoniazid metabolism in man. Br Med J. 1960 Aug 13;2(5197):485–491. doi: 10.1136/bmj.2.5197.485. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Eichelbaum M., Spannbrucker N., Steincke B., Dengler H. J. Defective N-oxidation of sparteine in man: a new pharmacogenetic defect. Eur J Clin Pharmacol. 1979 Sep;16(3):183–187. doi: 10.1007/BF00562059. [DOI] [PubMed] [Google Scholar]
  7. Evans D. A., Mahgoub A., Sloan T. P., Idle J. R., Smith R. L. A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population. J Med Genet. 1980 Apr;17(2):102–105. doi: 10.1136/jmg.17.2.102. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Gonzalez F. J., Skoda R. C., Kimura S., Umeno M., Zanger U. M., Nebert D. W., Gelboin H. V., Hardwick J. P., Meyer U. A. Characterization of the common genetic defect in humans deficient in debrisoquine metabolism. Nature. 1988 Feb 4;331(6155):442–446. doi: 10.1038/331442a0. [DOI] [PubMed] [Google Scholar]
  9. Idle J. R., Oates N. S., Shah R. R., Smith R. L. Protecting poor metabolizers, a group at high risk of adverse drug reactions. Lancet. 1983 Jun 18;1(8338):1388–1388. doi: 10.1016/s0140-6736(83)92172-4. [DOI] [PubMed] [Google Scholar]
  10. Inaba T., Tyndale R. E., Mahon W. A. Quinidine: potent inhibition of sparteine and debrisoquine oxidation in vivo. Br J Clin Pharmacol. 1986 Aug;22(2):199–200. doi: 10.1111/j.1365-2125.1986.tb05251.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Jacqz E., Hall S. D., Branch R. A. Genetically determined polymorphisms in drug oxidation. Hepatology. 1986 Sep-Oct;6(5):1020–1032. doi: 10.1002/hep.1840060534. [DOI] [PubMed] [Google Scholar]
  12. Kates R. E., Yee Y. G., Winkle R. A. Metabolite cumulation during chronic propafenone dosing in arrhythmia. Clin Pharmacol Ther. 1985 Jun;37(6):610–614. doi: 10.1038/clpt.1985.97. [DOI] [PubMed] [Google Scholar]
  13. Klein R. C., Huang S. K., Marcus F. I., Horwitz L., Fenster P. E., Rushforth N., Kirsten E. B. Enhanced antiarrhythmic efficacy of propafenone when used in combination with procainamide or quinidine. Am Heart J. 1987 Sep;114(3):551–558. doi: 10.1016/0002-8703(87)90752-6. [DOI] [PubMed] [Google Scholar]
  14. Küpfer A., Schmid B., Preisig R., Pfaff G. Dextromethorphan as a safe probe for debrisoquine hydroxylation polymorphism. Lancet. 1984 Sep 1;2(8401):517–518. doi: 10.1016/s0140-6736(84)92591-1. [DOI] [PubMed] [Google Scholar]
  15. LEPESCHKIN E., SURAWICZ B. The measurement of the Q-T interval of the electrocardiogram. Circulation. 1952 Sep;6(3):378–388. doi: 10.1161/01.cir.6.3.378. [DOI] [PubMed] [Google Scholar]
  16. Leemann T., Dayer P., Meyer U. A. Single-dose quinidine treatment inhibits metoprolol oxidation in extensive metabolizers. Eur J Clin Pharmacol. 1986;29(6):739–741. doi: 10.1007/BF00615971. [DOI] [PubMed] [Google Scholar]
  17. Lennard M. S., Silas J. H., Freestone S., Ramsay L. E., Tucker G. T., Woods H. F. Oxidation phenotype--a major determinant of metoprolol metabolism and response. N Engl J Med. 1982 Dec 16;307(25):1558–1560. doi: 10.1056/NEJM198212163072505. [DOI] [PubMed] [Google Scholar]
  18. Mahgoub A., Idle J. R., Dring L. G., Lancaster R., Smith R. L. Polymorphic hydroxylation of Debrisoquine in man. Lancet. 1977 Sep 17;2(8038):584–586. doi: 10.1016/s0140-6736(77)91430-1. [DOI] [PubMed] [Google Scholar]
  19. Morgan M. Y., Reshef R., Shah R. R., Oates N. S., Smith R. L., Sherlock S. Impaired oxidation of debrisoquine in patients with perhexiline liver injury. Gut. 1984 Oct;25(10):1057–1064. doi: 10.1136/gut.25.10.1057. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Møller J. V., Sheikh M. I. Renal organic anion transport system: pharmacological, physiological, and biochemical aspects. Pharmacol Rev. 1982 Dec;34(4):315–358. [PubMed] [Google Scholar]
  21. Oates N. S., Shah R. R., Idle J. R., Smith R. L. Phenformin-induced lacticacidosis associated with impaired debrisoquine hydroxylation. Lancet. 1981 Apr 11;1(8224):837–838. doi: 10.1016/s0140-6736(81)92711-2. [DOI] [PubMed] [Google Scholar]
  22. Okey A. B., Roberts E. A., Harper P. A., Denison M. S. Induction of drug-metabolizing enzymes: mechanisms and consequences. Clin Biochem. 1986 Apr;19(2):132–141. doi: 10.1016/s0009-9120(86)80060-1. [DOI] [PubMed] [Google Scholar]
  23. Otton S. V., Inaba T., Kalow W. Competitive inhibition of sparteine oxidation in human liver by beta-adrenoceptor antagonists and other cardiovascular drugs. Life Sci. 1984 Jan 2;34(1):73–80. doi: 10.1016/0024-3205(84)90332-1. [DOI] [PubMed] [Google Scholar]
  24. Shah R. R., Oates N. S., Idle J. R., Smith R. L., Lockhart J. D. Impaired oxidation of debrisoquine in patients with perhexiline neuropathy. Br Med J (Clin Res Ed) 1982 Jan 30;284(6312):295–299. doi: 10.1136/bmj.284.6312.295. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Siddoway L. A., Thompson K. A., McAllister C. B., Wang T., Wilkinson G. R., Roden D. M., Woosley R. L. Polymorphism of propafenone metabolism and disposition in man: clinical and pharmacokinetic consequences. Circulation. 1987 Apr;75(4):785–791. doi: 10.1161/01.cir.75.4.785. [DOI] [PubMed] [Google Scholar]
  26. Speirs C. J., Murray S., Boobis A. R., Seddon C. E., Davies D. S. Quinidine and the identification of drugs whose elimination is impaired in subjects classified as poor metabolizers of debrisoquine. Br J Clin Pharmacol. 1986 Dec;22(6):739–743. doi: 10.1111/j.1365-2125.1986.tb02969.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Testa B., Jenner P. Inhibitors of Cytochrome P-450s and their mechanism of action. Drug Metab Rev. 1981;12(1):1–117. doi: 10.3109/03602538109011082. [DOI] [PubMed] [Google Scholar]
  28. Thompson K. A., Iansmith D. H., Siddoway L. A., Woosley R. L., Roden D. M. Potent electrophysiologic effects of the major metabolites of propafenone in canine Purkinje fibers. J Pharmacol Exp Ther. 1988 Mar;244(3):950–955. [PubMed] [Google Scholar]
  29. Valenzuela C., Delgado C., Tamargo J. Electrophysiological effects of 5-hydroxypropafenone on guinea pig ventricular muscle fibers. J Cardiovasc Pharmacol. 1987 Nov;10(5):523–529. doi: 10.1097/00005344-198711000-00005. [DOI] [PubMed] [Google Scholar]
  30. Wagner F., Jähnchen E., Trenk D., Eichelbaum M., Harnasch P., Hauf G., Roskamm H. Severe complications of antianginal drug therapy in a patient identified as a poor metabolizer of metoprolol, propafenone, diltiazem, and sparteine. Klin Wochenschr. 1987 Dec 15;65(24):1164–1168. doi: 10.1007/BF01733250. [DOI] [PubMed] [Google Scholar]
  31. Walle T., Walle U. K., Olanoff L. S., Conradi E. C. Partial metabolic clearances as determinants of the oral bioavailability of propranolol. Br J Clin Pharmacol. 1986 Sep;22(3):317–323. doi: 10.1111/j.1365-2125.1986.tb02893.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. von Philipsborn G., Gries J., Hofmann H. P., Kreiskott H., Kretzschmar R., Müller C. D., Raschack M., Teschendorf H. J. Pharmacological studies on propafenone and its main metabolite 5-hydroxypropafenone. Arzneimittelforschung. 1984;34(11):1489–1497. [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES